Conference Coverage

ctDNA shows clinical value in advanced breast cancer


 

REPORTING FROM SABCS 2019


Secondary objectives included frequency of targetable mutations, accuracy of ctDNA testing (to be reported later), and others.

Results showed that ESR1 mutations were most common within the original population (27.7%), followed by AKT1 mutations (4.2%) and HER2 mutations (2.7%). In the treatment cohort, more than half of the patients had a HER2 mutation (58%) and/or an AKT1 mutation (54%), whereas a smaller proportion had an ESR1 mutation (38%). Approximately two-thirds of patients (64%) had hormone receptor–positive, HER2-negative breast cancer; 17% had triple-negative breast cancer; 6% had hormone receptor–positive, HER2-positive disease; 3% had hormone receptor–negative, HER2-positive disease; and 9% had other/unknown phenotypes. Approximately two-thirds of patients (65%) had received at least two lines of prior therapy for advanced disease.

For patients with an ESR1 mutation treated with extended-dose fulvestrant (cohort A) only 8.1% achieved a response, which was below the threshold for inferred efficacy. For patients with a HER2 mutation treated with neratinib with or without fulvestrant (cohort B), 25.0% had a response, thereby demonstrating inferred efficacy. Efficacy was also inferred in patients with an AKT1 mutation treated with capivasertib plus fulvestrant (cohort C), as 22.2% of these patients had a response. In the AKT basket (cohort D), 10.5% of patients had a response, which fell below the efficacy threshold; however, an exploratory analysis of this cohort showed that patients with an AKT1 mutation had a response rate of 33.3% (two out of six patients), which did meet efficacy criteria.

Adverse events were consistent with previous reports. The investigators noted that extended-dose fulvestrant was well tolerated.

“In conclusion, we show that circulating tumor DNA testing offers a simple, efficient and relatively fast method of tumor genotyping,” Dr. Turner said.

The investigators disclosed relationships with Puma Biotechnology, AstraZeneca, Guardant Health, and Bio-Rad.

SOURCE: Turner et al. SABCS. 2019 Dec 12. Abstract GS3-06.

Pages

Recommended Reading

CTS5 score partially validated for predicting late distant breast cancer recurrences
MDedge Hematology and Oncology
ctDNA, CTCs predict TNBC relapse – now what?
MDedge Hematology and Oncology
First report from NeoTRIPaPDL1: No pCR benefit with atezolizumab in TNBC
MDedge Hematology and Oncology
TNBC: Weekly nab-paclitaxel delivers, denosumab disappoints
MDedge Hematology and Oncology
New evidence informs discussions on FL treatment and breast screening
MDedge Hematology and Oncology
PEARL lacks luster in metastatic breast cancer progressing on AIs
MDedge Hematology and Oncology
Oral paclitaxel bests IV version for tumor response, neuropathy incidence in mBC
MDedge Hematology and Oncology
Chemotherapy better for metastatic breast cancer maintenance than durvalumab
MDedge Hematology and Oncology
Neoadjuvant cisplatin fails to beat standard AC in HER2-negative breast cancer
MDedge Hematology and Oncology
Sensitivity of ctDNA equivalent to that of tumor tissue sequencing
MDedge Hematology and Oncology